Deferred combined androgen blockade therapy using antiandrogen in hormone-refractory metastatic prostate cancer patients treated with Degarelix, GnRH antagonist

Deferred combined androgen blockade therapy using antiandrogen in hormone-refractory metastatic prostate cancer patients treated with Degarelix, GnRH antagonist - Deferred combined androgen blockade therapy using antiandrogen in hormone-refractory metastatic prostate cancer patients treated with Degarelix, GnRH antagonist

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011437

Enrollment

200

Registered

2013-08-09

Start date

2013-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone metastatic prostate cancer

Interventions

Starting with Degarelix monotherapy. Additive Bicalutamide will be used in case of PSA recurrence. Bicalutamide will be replaced with Flutamide when second PSA recurrence occurs.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Histologically proven bone metastatic prostate cancer (adenocarcinoma). 2) A male patient in whom endocrine treatment is indicated.

Exclusion criteria

Exclusion criteria: Previous or present endocrine treatment for prostate cancer.

Design outcomes

Primary

Measure	Time frame
Changes in serum level of Prostate Specific Antigen (PSA) over time	—

Countries

Japan

Contacts

Public ContactMotohide Uemura

Osaka University Graduate School of Medicine Department of Organ Specific Regulation (Urology)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026